Cullinan Therapeutics, Inc.CGEMNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-31.23%
↓ 278% below average
Average (26q)
17.60%
Historical baseline
Range
High:199.45%
Low:-47.42%
Volatility
1403.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -31.23% |
| Q2 2025 | 47.21% |
| Q1 2025 | 2.39% |
| Q4 2024 | 14.04% |
| Q3 2024 | -2.08% |
| Q2 2024 | 18.32% |
| Q1 2024 | -12.06% |
| Q4 2023 | 3.04% |
| Q3 2023 | 23.47% |
| Q2 2023 | -47.42% |
| Q1 2023 | 144.34% |
| Q4 2022 | 8.34% |
| Q3 2022 | -25.49% |
| Q2 2022 | 7.64% |
| Q1 2022 | 17.52% |
| Q4 2021 | 64.65% |
| Q3 2021 | 7.66% |
| Q2 2021 | -5.13% |
| Q1 2021 | -25.34% |
| Q4 2020 | 67.75% |
| Q3 2020 | -20.67% |
| Q2 2020 | 199.45% |
| Q1 2020 | 9.76% |
| Q4 2019 | -27.94% |
| Q3 2019 | 36.86% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |